Amgen Sues Aurobindo to Block Copies of Parsabiv Kidney Drug

Amgen and its Kai Pharmaceuticals unit said Aurobindo’s proposed generic version of Parsabiv, an injectable treatment for kidney disease, infringes two patents for the drug.

• Amgen is seeking a court order blocking copies until the patents have expired, according to complaint filed Thursday in federal court in Wilmington, Delaware
• Patents cover stable liquid formulation of etelcalcetide, Parsabiv’s active ingredient, and expire in June 2034: FDA Orange Book
• Parsabiv is for treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis, complaint says
• Parsabiv had U.S. sales of $605 million in 2020, 10% higher than in 2019: data ...